HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MOBI

Mobia Medical, Inc. (NASDAQ)

Healthcare — Medical Devices

Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.

None 5 analysts
$13.16
$-0.24 (-1.79%)
Target: $20.00 (52.0%)
Sign in to add MOBI to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$437.56M
P/E Ratio (TTM)-
Forward P/E-6.14
EPS (TTM)$-1.62
Dividend Yield-
Profit Margin-139.35%
Revenue Growth113.30%
ROE-
Debt/Equity409.26
Recommendation None
Analyst Target$20.00
Analysts5
Indexes NASDAQ

Technical Indicators

RSI (14)52.2
Beta-
SMA 20-
SMA 40-
52-Week High$15.29
52-Week Low$10.19
50-Day Avg$12.95
200-Day Avg$12.95
Avg Volume249.3K
Volume139.4K

Performance Analysis

BULLISH

MOBI shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 58% of its 52-week range.
~ RSI at 52.2 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 113.3% year-over-year.
- Operating at a loss with -139.3% margin.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $20.00 implies 52.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:20 UTC

Back to Screener Export Report